The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.
The company's test boasted strong sensitivity and specificity for a range of different alterations in clinical and contrived samples, particularly for low-allele frequencies.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.
The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.
An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.
The trial aims to demonstrate the utility of Biocept's Target Selector PD-L1 assay in patients diagnosed with non-small cell lung cancer.
In Cell this week: integrated genomic analysis of adult soft tissue sarcoma, positive selection has greater role in cancer than negative selection, and more.
The WIN Consortium's Catherine Bresson discusses the association's approach for treating cancer patients at the Independent.
A Mount Sinai team performed targeted sequencing on non-small cell lung cancer samples to find mutations with clinical implications.
Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.
The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.
Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.
In Nature this week: ash dieback disease fungal genome, and more.